TBPH Theravance Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TBPH

Price (delayed)

$10.25

Market cap

$498.49M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.88

Enterprise value

$491.72M

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives ...

Highlights
TBPH's revenue is up by 27% year-on-year and by 7% since the previous quarter
The gross profit has grown by 27% YoY and by 7% from the previous quarter
Theravance Biopharma's EPS has shrunk by 107% YoY but it has increased by 12% QoQ
The net income has plunged by 105% YoY but it has grown by 19% from the previous quarter
TBPH's equity is down by 45% year-on-year and by 3.8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.theravance.com
Peers: MDWD MEIP CTLT CPRX

Key stats

What are the main financial stats of TBPH
Market
Shares outstanding
48.63M
Market cap
$498.49M
Enterprise value
$491.72M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.41
Price to sales (P/S)
8.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.99
Earnings
Revenue
$61.51M
EBIT
-$34.76M
EBITDA
-$28.73M
Free cash flow
-$17.14M
Per share
EPS
-$0.88
Free cash flow per share
-$0.35
Book value per share
$4.25
Revenue per share
$1.27
TBVPS
$7.69
Balance sheet
Total assets
$371.31M
Total liabilities
$166.44M
Debt
$47.9M
Equity
$204.87M
Working capital
$102.63M
Liquidity
Debt to equity
0.23
Current ratio
5.74
Quick ratio
5.33
Net debt/EBITDA
0.24
Margins
EBITDA margin
-46.7%
Gross margin
100%
Net margin
-72.8%
Operating margin
-68.8%
Efficiency
Return on assets
-11.1%
Return on equity
-19%
Return on invested capital
-9.6%
Return on capital employed
-9.9%
Return on sales
-56.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
0.39%
1 week
7.11%
1 month
21.88%
1 year
6.77%
YTD
-8.81%
QTD
20.87%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$61.51M
Gross profit
$61.51M
Operating income
-$42.33M
Net income
-$44.77M
Gross margin
100%
Net margin
-72.8%
The net income has plunged by 105% YoY but it has grown by 19% from the previous quarter
Theravance Biopharma's net margin has shrunk by 104% YoY but it has increased by 24% QoQ
Theravance Biopharma's operating margin has surged by 58% YoY and by 30% QoQ
The operating income is up by 47% YoY and by 24% QoQ

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
P/E
N/A
P/B
2.41
P/S
8.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.99
Theravance Biopharma's EPS has shrunk by 107% YoY but it has increased by 12% QoQ
TBPH's equity is down by 45% year-on-year and by 3.8% since the previous quarter
The price to book (P/B) is 10% higher than the last 4 quarters average of 2.2
The P/S is 42% lower than the 5-year quarterly average of 13.9 and 14% lower than the last 4 quarters average of 9.4
TBPH's revenue is up by 27% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Theravance Biopharma business performance
The company's return on assets has shrunk by 107% YoY but it rose by 10% QoQ
The ROE has plunged by 105% YoY but it has grown by 4.5% from the previous quarter
The ROIC has plunged by 104% YoY but it has grown by 24% from the previous quarter
Theravance Biopharma's return on sales has shrunk by 103% YoY but it has increased by 31% QoQ

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 123% more than its total liabilities
The company's quick ratio fell by 45% YoY but it rose by 9% QoQ
TBPH's current ratio is down by 42% year-on-year but it is up by 6% since the previous quarter
Theravance Biopharma's debt is 77% lower than its equity
The debt to equity has soared by 64% YoY
TBPH's equity is down by 45% year-on-year and by 3.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.